TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

By

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies

By

TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

By

TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

By

TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting

By

TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones

By

TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting

By

TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance

By

TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities

By

TScan Therapeutics to Participate in Upcoming Investor Conferences

By